Amgen, Cytokinetics Add Japan to Heart Failure Collaboration
Genetic Engineering News
Amgen and Cytokinetics said today they will expand a seven-year-old collaboration by extending to Japan their license agreement for omecamtiv mecarbil, a heart failure treatment now in clinical trials, and related compounds, in a deal that could net ...
Amgen Expands Licensing DealLos Angeles Business Journal
AMGEN, INC. : Amgen and Cytokinetics Announce Expansion of License for ...4-traders (press release)
Cytokinetics and Amgen expand collaborationBusinessweek
FierceBiotech -Seeking Alpha
all 9 news articles »